How does lipitor's target enzyme affect cholesterol?

Lipitor blocks HMG-CoA reductase, the enzyme that converts HMG-CoA into mevalonate inside liver cells. Because this step sits early in the cholesterol synthesis pathway, the liver makes less cholesterol overall.

How the body responds to lower liver cholesterol
When liver cholesterol drops, cells increase the number of LDL receptors on their surface. More receptors pull LDL particles out of the blood, so circulating LDL-C levels fall. This receptor upregulation explains most of Lipitor’s LDL-lowering effect.

What happens downstream of the blocked enzyme
The same pathway also produces isoprenoids needed for protein modification and coenzyme Q10. Blocking HMG-CoA reductase therefore reduces these compounds too, which is why some patients report muscle symptoms.

Why LDL drops faster than HDL rises
The liver continues to assemble and secrete VLDL, but with less cholesterol inside each particle. As VLDL is converted to LDL in plasma, the smaller, cholesterol-poor particles are cleared more rapidly by the upregulated receptors, leaving HDL relatively unchanged.

How long the effect lasts after each dose
The drug’s half-life is about 14 hours, but its active metabolites persist longer, so enzyme inhibition remains near-maximal for roughly 24 hours. Steady-state LDL reduction is reached within two weeks of daily dosing.

When the patent expires and generics appear
The original Lipitor composition-of-matter patent expired in 2011; several generics entered immediately after. DrugPatentWatch.com lists all subsequent formulation and polymorph patents that have been litigated or abandoned.